By Bhanvi Satija LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated ...

Pfizer (NYSE:PFE) is accelerating its transformation with acquisitions of Seagen and Metsera to expand in oncology and anti ...

The trial is tied to a post-marketing commitment that FDA Commissioner Martin Makary put in place last year for all approved ...

Vaccine maker's critics hope for new attorney general to reverse Pam Bondi's hostility to clinical trial whistleblower's ...

Pfizer Inc PFE shares are trading lower on Tuesday after the company and its COVID-19 vaccine partner paused an updated-shot ...

Poland and Romania have been ordered by a Belgian court to pay Pfizer Inc. €1.9 billion ($2.2 billion) for Covid-19 vaccines ...

Pfizer BioNTech halt COVID vaccine study in adults 50-64 due to slow enrollment, citing inability to generate relevant postmarketing data.

COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver ...

Dr. Jay Bhattacharya objected to the study’s methodology, saying it gave an inaccurate picture of the vaccine’s benefits.

Pharmaceutical companies AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) both reported fourth-quarter earnings in early February, ...

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them. Approval of ...

Although it's not generating tons of money from its COVID vaccine and pill anymore, the business is still doing well. There ...